Browsing by Subject "Incidence"

Now showing 1 - 6 of 6
  • Thumbnail Image
    Publication
    Open Access
    Bayesian estimates of the incidence of rare cancers in Europe
    (Elsevier, 2018-06) Botta, L; Capocaccia, R; Trama, A; Herrmann, C; Salmerón, D; De Angelis, R; Mallone, S; Bidoli, E; Marcos- Gragera, R; Dudek-Godeau, D; Gatta, G; Cleries, R; Ciencias Sociosanitarias
    Background: The RARECAREnet project has updated the estimates of the burden of the 198 rare cancers in each European country. Suspecting that scant data could affect the reliability of statistical analysis, we employed a Bayesian approach to estimate the incidence of these cancers. Methods: We analyzed about 2,000,000 rare cancers diagnosed in 2000–2007 provided by 83 population-based cancer registries from 27 European countries. We considered European incidence rates (IRs), calculated over all the data available in RARECAREnet, as a valid a priori to merge with country-specific observed data. Therefore we provided (1) Bayesian estimates of IRs and the yearly numbers of cases of rare cancers in each country; (2) the expected time (T) in years needed to observe one new case; and (3) practical criteria to decide when to use the Bayesian approach. Results: Bayesian and classical estimates did not differ much; substantial differences (> 10%) ranged from 77 rare cancers in Iceland to 14 in England. The smaller the population the larger the number of rare cancers needing a Bayesian approach. Bayesian estimates were useful for cancers with fewer than 150 observed cases in a country during the study period; this occurred mostly when the population of the country is small. Conclusion: For the first time the Bayesian estimates of IRs and the yearly expected numbers of cases for each rare cancer in each individual European country were calculated. Moreover, the indicator T is useful to convey incidence estimates for exceptionally rare cancers and in small countries; it far exceeds the professional lifespan of a medical doctor.
  • Thumbnail Image
    Publication
    Open Access
    Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
    (Elsevier, 2022-11) Aguado de la Rosa, Carlos; Cruz Castellanos, Patricia; Lázaro Quintela, Martín; Dómine, Manuel; Vázquez Estévez, Sergio; López Vivanco, Guillermo; Fírvida Pérez, José Luis; Alonso Romero, José Luis; Ferrera Delgado, Lioba; García Girón, Carlos; Diz Taín, Pilar; Álvarez Álvarez, Rosa; Mut Sanchís, Pilar; Fernández Cantón, Inmaculada; Manrique Abós, Isabel; Martínez Aguillo, Maite; Gómez-Aldaraví Gutiérrez, Lorenzo; Ortega Granados, Ana Laura; Álvarez Cabellos, Ruth; García Sebastián, Arancha; García Sifuentes, Luis Fernando; Reguart, Noemí; Medicina
    Objectives To determine the incidence of ALK translocations in patients with advanced/metastatic NSCLC in Spain, to describe the clinical characteristics of these patients, and to evaluate the effectiveness and safety of treatment with crizotinib in a real-world setting. Methods This is an observational prospective and retrospective cohort study to determine the incidence of ALK translocations and to analyze the effectiveness and safety of crizotinib in a real-world setting. Patient characteristics, treatment patterns, time to best overall response, duration of treatment, objective response rates (ORR), rates of adverse events (AE), progression free survival (PFS) and overall survival (OS) were evaluated in the ALK study cohort of patients treated with crizotinib (prospective and retrospective). ALK incidence and quality of life (QoL) questionnaires were measured from patients included in the prospective cohort. Results The incidence of ALK translocations was 5.5 % (31 of 559 patients). Compared with ALK-negative patients, ALK-positive patients were significantly younger, predominantly female, and non-smokers. In the crizotinib effectiveness and safety study, 91 patients (42 prospective, 49 retrospective) with ALK-positive NSCLC (43.9 % in first-line, 56.1 % in second or more lines) were included. The ORR was 59.3 % and the median duration of response was 13.5 months (IQR, 5.3–26.2). The median PFS was 15.8 months (95 % CI, 11.8–22.3) and the median OS was 46.5 months, with 53 patients (58.2 %) still alive at data cut-off date. Frequently reported AEs included elevated transaminases, gastrointestinal disorders, and asthenia. Most patients (76.5 %) reported improved or stable scores for global QoL during treatment. Conclusions The observed incidence of ALK translocations in NSCLC patients is aligned with published reports. This analysis of the real-world clinical experience in Spain confirms the therapeutic benefit and safety of crizotinib in advanced/metastatic ALK-positive NSCLC.
  • Thumbnail Image
    Publication
    Open Access
    Incidence and trend of type I and II endometrial cancer in women from two population-based european cancer registries (1998–2012)
    (MDPI, 2022-03-23) Rodríguez-Palacios, Daniel Ángel; Colorado-Yohar, Sandra M.; Velten, Michel; Vaamonde-Martín, Ricardo J.; Ballesta Ruiz, Mónica; Chirlaque López, María Dolores; Ciencias Sociosanitarias; Facultad de Enfermería
    Endometrial cancer (EC) is the most frequent female genital tract cancer in Europe. This cohort study aimed to determine age-standardised incidence rates and long-term trends of type I and II endometrial cancer in women from population-based cancer registries in the Region of Murcia (Spain) and the Bas-Rhin area (France). Data of new cases of endometrial cancer between 1998 and 2012 were obtained from the Murcia and Bas-Rhin cancer registries. In that period, 3756 cases of endometrial cancer were recorded, with 3270 corresponding to type I EC and 486 corresponding to type II EC. The Bas-Rhin area presented higher age-adjusted incidence rates than those in the Region of Murcia for both type I EC (24.2 and 19.3 cases/100,000 person-years (py), respectively) and type II EC (4.4 and 2.3 cases/100,000 py, respectively). Joinpoint regression showed no changes in trends. In both populations, there was an increasing trend for both EC types, but the trend was steeper in the Region of Murcia and larger overall for type II EC. Finally, a significant increase was observed in the annual trend of type II EC. Further studies are warranted to determine the potential risk factors, and continued efforts are needed to improve the recording and monitoring of EC types.
  • Thumbnail Image
    Publication
    Open Access
    Incidence trends and main features of Gastro-Intestinal Stromal Tumours in a Mediterranean region: a population-based study
    (MDPI, 2023-05-30) Vaamonde Martín, Ricardo J.; Ballesta Ruiz, Mónica; Sánchez Gil, Antonia; Fernández Hernández, Juan Ángel; Martínez Barba, Enrique; Martínez García, Jerónimo; Gatta, Gemma; Chirlaque López, María Dolores; Ciencias Sociosanitarias; Facultades de la UMU::Facultad de Enfermería
    Gastro-Intestinal Stromal Tumours (GISTs) are a kind of neoplasm whose diagnosis in common clinical practice just started in the current century, implying difficulties for proper registration. Staff from the Cancer Registry of Murcia, in southeastern Spain, were commissioned by the EU Joint Action on Rare Cancers into a pilot study addressing GIST registration that also yielded a population-based depiction of GISTs in the region, including survival figures. We examined reports from 2001 to 2015 from hospitals as well as cases already present in the registry. The variables collected were sex, date of diagnosis, age, vital status, primary location, presence of metastases, and risk level according to Joensuu’s Classification. In total, 171 cases were found, 54.4% occurred in males, and the mean age value was 65.0 years. The most affected organ was the stomach, with 52.6% of cases. Risk level was determined as “High” for 45.0%, with an increment of lower levels in recent years. Incidence for the year 2015 doubled that of 2001. Overall, the 5-year net survival estimation was 77.0%. The rising incidence magnitude is consistent with trends in other European countries. Survival evolution lacked statistical significance. A more interventional approach in clinical management could explain the increase in the proportion of “Low Risk GISTs” and the first occurrence of “Very Low Risk” in recent years.
  • Thumbnail Image
    Publication
    Open Access
    Psychiatric comorbidity in intellectual developmental disorders: a systematic review
    (MA Healthcare , 2025-07-04) Astilleros Martínez, Borja; Martín Chaparro, María del Pilar; Kotera, Yasuhiro ; Psiquiatría y Psicología Social; Facultad de Psicología y Logopedia
    Aims/Background Intellectual developmental disorders (IDD) are characterized by significant limita-tions in intellectual functioning and adaptive behavior, affecting conceptual, social, and practical skills. They impact 1% of the global population, with mild cases being more common. Major causes include prenatal, perinatal, and postnatal factors, although a clear cause is often not identified. This study aims to evaluate the comorbidity of psychological disorders in individuals diagnosed with IDD. Methods Following the “Preferred Reporting Items for Systematic reviews and Meta-Analyses” (PR-ISMA) statement, studies from 2014 to 2024 were considered using the databases Web of Science, PsycInfo, and PubMed. Articles focusing on psychopathology in individuals with IDD from birth were selected, excluding studies involving individuals under 16 years old and cases of severe and profound IDD. Results Of the 2895 articles retrieved, 11 were included. These studies showed heterogeneity in co-morbidities such as schizophrenia spectrum and other psychotic disorders, mood disorders, anxiety disorders, developmental disorders, personality disorders, substance use disorders, and adjustment and stress reaction disorders. Conclusion Individuals with IDD are more vulnerable to mental health conditions, underscoring the need for comprehensive assessments and multidisciplinary treatments to improve their quality of life and optimize public resources. Future research should develop validated diagnostic tools for IDD and conduct longitudinal studies on their impact on quality of life. It should also explore gender differences and address specific needs in disadvantaged contexts with tailored interventions.
  • Thumbnail Image
    Publication
    Open Access
    Shifting epidemiology of pancreatic cancer in Southeast Spain (1983-2018): emerging patterns in younger women and neuroendocrine neoplasms
    (2026-02-17) Colorado-Yohar, Sandra M.; Vaamonde-Martín, Ricardo J.; Ballesta Ruiz, Mónica; Salmerón Martínez, Diego; Marcos-Gragera, Rafael; Sánchez-Gil, Antonia; Corral de la Calle, Javier; Chirlaque López, María Dolores; Ciencias Sociosanitarias